Drug intelligence / Profile preview

WX-mPD-1

Development stage: Preclinical
Lead developer: WuXi AppTec
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

WX-mPD-1 is a preclinical-stage anti-mouse PD-1 monoclonal antibody developed by WuXi AppTec and WuXi Biologics. It serves as a surrogate immune checkpoint inhibitor for use in syngeneic mouse xenograft models, such as CloudmanS91 and B16-F10 melanoma, to evaluate the efficacy and mechanism of action of PD-1 blockade. Research using WX-mPD-1 has focused on immune profiling, neo-antigen identification, and TCR repertoire analysis to better understand immune responses to checkpoint inhibition in preclinical settings.

Other names: anti-mouse PD-1 antibody

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on WX-mPD-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WX-mPD-1.

Explore the full profile